Looking for the Holy Grail—Drug candidates for glioblastoma multiforme chemotherapy
B Pająk - Biomedicines, 2022 - mdpi.com
Glioblastoma multiforme (GBM) is the deadliest and the most heterogeneous brain cancer.
The median survival time of GBM patients is approximately 8 to 15 months after initial …
The median survival time of GBM patients is approximately 8 to 15 months after initial …
Pharmacokinetic approach in therapeutic monitoring of antineoplastic drugs and the impact on pharmacoeconomics: A systematic review
IAB Barbosa, TC Silva, MVP Souza… - Journal of Oncology …, 2023 - journals.sagepub.com
Objectives Therapeutic drug monitoring aims to quantify the concentration of a drug in a
biological matrix. In oncology, the therapeutic arsenal is vast and therapeutic drug …
biological matrix. In oncology, the therapeutic arsenal is vast and therapeutic drug …
[PDF][PDF] Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy. Biomedicines 2022, 10, 1001
B Pająk - 2022 - researchgate.net
Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy
Page 1 Biomedicines 2022, 10, 1001. https://doi.org/10.3390/biomedicines10051001 www.mdpi.com/journal/biomedicines …
Page 1 Biomedicines 2022, 10, 1001. https://doi.org/10.3390/biomedicines10051001 www.mdpi.com/journal/biomedicines …